Market View Minutes with Michelle: Can Pfizer sustain its record gains for the mid-to-long term?

Pfizer is due to release its earnings in the US tonight and the stage is set for what's been dubbed "record-shattering revenues", and analysts believe two new products will bring sales beyond the US$1 billion mark. But can the pharmaceutical giant sustain these gains  in the medium to long term? Michelle Martin finds out. 

See omnystudio.com/listener for privacy information.